Presymptomatic studies in ALS: rationale, challenges, and approach
about
Increased functional connectivity common to symptomatic amyotrophic lateral sclerosis and those at genetic riskWhat does imaging reveal about the pathology of amyotrophic lateral sclerosis?Biomarkers of Brain Structure and Function for Neurodegenerative Disorders: Are They Adequate for Go/No Go Decisions in Drug Development?Multiple kernel learning captures a systems-level functional connectivity biomarker signature in amyotrophic lateral sclerosis.Virtual brain biopsies in amyotrophic lateral sclerosis: Diagnostic classification based on in vivo pathological patternsWidespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis.Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research.Controversies and priorities in amyotrophic lateral sclerosis.The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosisNeurofilament light chain: a biomarker for genetic frontotemporal dementiaLongitudinal imaging in C9orf72 mutation carriers: Relationship to phenotype.Psychiatric disorders prior to amyotrophic lateral sclerosis.Altered cortical beta-band oscillations reflect motor system degeneration in amyotrophic lateral sclerosis.Amyotrophic lateral sclerosis: a long preclinical period?Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis.The expanding syndrome of amyotrophic lateral sclerosis: a clinical and molecular odysseyPresymptomatic ALS genetic counseling and testing: Experience and recommendations.Further development of biomarkers in amyotrophic lateral sclerosis.Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis.Predictive genetic testing for amyotrophic lateral sclerosis and frontotemporal dementia: genetic counselling considerations.Biological follow-up in amyotrophic lateral sclerosis: decrease in creatinine levels and increase in ferritin levels predict poor prognosis.Opportunity and innovation in studying pre-symptomatic amyotrophic lateral sclerosis.ALS-Related Mutant FUS Protein Is Mislocalized to Cytoplasm and Is Recruited into Stress Granules of Fibroblasts from Asymptomatic FUS P525L Mutation Carriers.ALFF Value in Right Parahippocampal Gyrus Acts as a Potential Marker Monitoring Amyotrophic Lateral Sclerosis Progression: a Neuropsychological, Voxel-Based Morphometry, and Resting-State Functional MRI Study.Downregulated Glia Interplay and Increased miRNA-155 as Promising Markers to Track ALS at an Early Stage.Small RNA Sequencing of Sporadic Amyotrophic Lateral Sclerosis Cerebrospinal Fluid Reveals Differentially Expressed miRNAs Related to Neural and Glial Activity.Patient-centered decision making in amyotrophic lateral sclerosis: where are we?Increased cerebral functional connectivity in ALS: A resting-state magnetoencephalography study.Advances in motor neurone disease.
P2860
Q24658568-F585405F-8BD4-46C7-8956-06D6E3FBB55CQ27007017-AE16211E-C778-475E-B7D1-B607811AC8E6Q30999044-40025A4F-E7F6-4583-AAC3-77C3246C8058Q31147229-6EFF2613-8A98-4A51-8519-08FCECF4E046Q33822826-6BE1BE63-BAB3-4848-BEDE-85616B95A740Q34044019-F86FAAE3-5EA3-409D-BF3A-22600034FE7EQ34401653-A85AB252-EFED-4A40-A770-282F280EE59EQ36045826-A2B0CCC1-CD58-4E57-883F-32AD14F8EF19Q36482355-50E09D5B-CA1F-47A2-9FF9-6186F2D7A2CDQ37208495-23F5E8EE-26DB-4AAF-A20C-BE015CC68D19Q37497445-349F6A74-DBD9-4D5A-8827-AB5BB4A13BF5Q37560930-97045066-F207-4565-BEC2-6D299DF2B27FQ37561488-C2698BC8-4851-4296-B892-53F49D38E609Q38197553-65E9A678-1CD2-4398-B7A3-880CFCA913D1Q38257430-9EC0F250-F658-446E-87B8-C0DF90CFA810Q38341406-C8462AB8-CC41-4517-A027-E29FCFB5AD93Q38838008-143BB27D-060F-444A-96A0-33862223A788Q38856405-01D9A50B-D785-419F-BA67-107F2E30F523Q38983572-85E6CE68-E839-4B75-9441-3B6E297CB6F1Q39354046-D1186012-2ABF-42FB-93A3-066376E929C5Q40814817-DC74F80F-8AEC-4EB5-8ABF-7EDCA4DD2859Q46114577-9007B826-DC70-42AB-A9B2-93F688B25B9FQ47647790-1CD146B4-8123-46EE-B7E9-A170656CBCCFQ48146205-9E1C4064-1715-41FA-9FCE-5932636C0EC0Q48281779-B979DDBA-C3CB-4AF7-8D56-4DAEC48CA380Q48505093-C5696C23-3CF6-4AF6-876C-0D7A02997254Q49818063-9EA3310B-8DAB-485C-9778-9CDA1ACDC4C6Q55361541-2AE5BDB4-A1D5-4EA5-9716-C92E60EBE2EFQ55545731-7C7013CC-6F39-4BC8-8CA5-F40D39CBB7E0
P2860
Presymptomatic studies in ALS: rationale, challenges, and approach
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Presymptomatic studies in ALS: rationale, challenges, and approach
@ast
Presymptomatic studies in ALS: rationale, challenges, and approach
@en
Presymptomatic studies in ALS: rationale, challenges, and approach
@nl
type
label
Presymptomatic studies in ALS: rationale, challenges, and approach
@ast
Presymptomatic studies in ALS: rationale, challenges, and approach
@en
Presymptomatic studies in ALS: rationale, challenges, and approach
@nl
prefLabel
Presymptomatic studies in ALS: rationale, challenges, and approach
@ast
Presymptomatic studies in ALS: rationale, challenges, and approach
@en
Presymptomatic studies in ALS: rationale, challenges, and approach
@nl
P2860
P3181
P1433
P1476
Presymptomatic studies in ALS: rationale, challenges, and approach
@en
P2093
P2860
P304
P3181
P356
10.1212/WNL.0B013E31826E9B1D
P407
P577
2012-10-16T00:00:00Z